This page is a plain guide to hematology market research Saudi Arabia. Sickle cell disease and beta-thalassemia are inherited blood disorders. Hydroxyurea is a daily medicine used in sickle cell disease. A stem-cell transplant replaces blood-forming cells. Casgevy (exagamglogene autotemcel) is a one-time gene therapy. The Saudi Food and Drug Authority, the SFDA, authorised it on 9 January 2024 (Vertex). The sickle cell thalassemia market Saudi Arabia is not one number. A screening file and a clinic chart count different people. Read this with the healthcare market research hub, the Saudi Arabia page, and the ranking of hematology research firms.
What this kind of study is
It is commissioned work on who is diagnosed, who is treated, who pays, and which centre can give a one-time product. Grand View Research publishes a hematology diagnostics outlook of USD 18.3 million for 2024. That figure is instruments and reagents. It is not a count of patients with repeated pain crises, and it is not a formulary decision. 6Wresearch and Ken Research also sell diagnostics report pages. Use them for laboratory spend. Do not take them to a hospital committee as the gene-therapy file.
Premarital screening has been required under the Healthy Marriage programme, by Council of Ministers Resolution no. 4/B/54504 dated 15/11/1424 H (Ministry of Health). Government supply still runs through hospital pharmacy committees and, for national buying, NUPCO (PPRI 2024). The Council of Health Insurance formulary is a list of SFDA-registered medicines. Additions go through a hospital committee or the assigned medical director (CHI formulary).
For the wider setting, see SFDA market access and health-economics work in Saudi Arabia.
How common are sickle cell and thalassemia?
Do not average these rates. They use different tests and different ages. None of them is national demand for a medicine.
In 2004–2005, 488,315 people were screened. Sickle-cell trait was 4.20%. Sickle-cell disease was 0.26%. Thalassemia trait was 3.22%. Thalassemia disease was 0.07%. Of 2,375 high-risk couples reached by telephone, 89.6% were still married (Alhamdan et al., 2007).
From 2004 to 2009, 1,572,140 people were examined. Sickle-cell positivity was 45.1 per 1,000 (42.4 carriers and 2.7 cases). Beta-thalassemia positivity was 18.5 per 1,000 (18.0 carriers and 0.5 cases). At-risk couples fell from 10.1 to 4.0 per 1,000. Voluntary cancellation of those proposals rose from 9.2% to 51.9%. The East held 58% of detected at-risk marriages (Memish and Saeedi, 2011). In the same years the Eastern region was 134.1 per 1,000 for the sickle-cell gene and 59.0 per 1,000 for beta-thalassemia, against 13.5 to 13.7 per 1,000 for sickle cell in the Northern and Central regions (Memish et al., 2011).

From 2011 to 2018, Aljabry and colleagues used 1,871,184 people, mean age 30.2. Abnormal results were 6.0%. HbS was found in 88,431 people (4.7%): HbSA in 83,013 (4.4%) and HbSS in 4,728 (0.3%). Beta-thalassemia was found in 22,420 people (1.2%): 21,512 with trait and 908 with disease genotypes. Among sickle-cell disease presentations, 87.3% were HbSS, 12.5% were HbS-beta thalassemia, and 0.2% were HbSC or HbSD. The Eastern and Jazan regions were five and six times Riyadh. There was no clear 2011–2018 trend in sickle-cell trait (387 to 471 per 10,000) or sickle-cell disease (24 to 31 per 10,000) (Aljabry et al., 2024).
A 2011–2015 cut put sickle-cell trait at 135.7 per 1,000 in Jazan and 114.4 per 1,000 in the East, and sickle-cell disease at 9.8 per 1,000 in the East (Alsaeed et al., 2018). A review of Eastern newborn screening reported about 21% trait and 2.6% disease, higher than Eastern premarital figures of about 17% and 1.2%, because premarital screening misses children who do not reach marriage age. The same review describes a milder Eastern pattern and a more severe Western pattern (Jastaniah, 2011).
A community survey of 45,682 Saudi children and adolescents found 108 with sickle cell disease, or 24 per 10,000 (Al-Qurashi et al., 2008). Applying 1 to 3 per 1,000 to about 18.8 million Saudi nationals in the 2022 census, one paper estimated 18,800 to 56,000 people living with the disease (Al-Judaibi et al., 2025). Vertex’s approval note said “thousands” (Vertex). Those are three methods. Do not hide the range.
In mid-2024 the statistics authority estimated 35.3 million residents, 19.6 million of them Saudi and about 15.7 million not Saudi (GASTAT). Do not apply an Eastern screening rate to 35.3 million people and call it demand. The programme now runs through more than 160 government centres and more than 70 private centres (Al-Shroby et al., 2024).
What do the hydroxyurea studies show?
The published shares do not measure the same thing. Do not turn any one of them into a national treated share.
A review of 2,816 clinic records at Al-Qatif Central Hospital and King Fahad Hospital in Hofuf, from June 2021 to May 2023, found a hydroxyurea prescription in 56%. Younger patients were prescribed it more often. Hydroxyurea users were also more likely to have paracetamol, anti-inflammatory drugs and opioids prescribed. The authors read that pattern as a problem of staying on the medicine, not as proof that 56% were taking it (Alsaffar et al., 2024).
A 2022 Eastern survey of 202 patients and caregivers found 38.1% currently using hydroxyurea, 15.8% who had stopped, and 46% who had not used it. Among those who had not used it, 40.9% said it was not offered and 34.4% said they had not heard of it (Cureus, 2022). In Jazan, more than 80% of participating parents said one or more of their children were receiving hydroxyurea. That is a parent report about children. It is not a national adult share (Gohal et al., 2022).

A single-centre group of 156 patients (mean age 12.69; mean dose 16.52 mg/kg/day) reported a mean drop of 1.36 pain crises per patient per year after at least 12 months (Al-Anazi et al., 2022). At King Saud Medical City in Riyadh, 82 eligible children had an 80% reduction in crises and a 73% shorter stay (Bin-Saad et al., 2020). Those are local results. They are not a 2026 national tracker.
Two later medicines should not be assumed as a 2026 step from these papers. The European Medicines Agency recommended revoking crizanlizumab (Adakveo) on 26 May 2023 (EMA). The U.S. Food and Drug Administration wrote in September 2024 about Pfizer’s voluntary withdrawal of voxelotor (Oxbryta) (FDA). Ask what centres did after those notices. Do not invent an SFDA status that is not on an SFDA page.
What do transplant papers show?
A matched related-donor transplant is the curative option these centres have published. It is the comparison a Casgevy brief will be asked about.
Al-Jefri and colleagues reported 129 children, aged 14 or under at transplant, who received a matched related-donor transplant for severe sickle cell disease at King Faisal Specialist Hospital in Riyadh between January 2006 and December 2020. The reasons were cerebral vessel disease in 74 (57%), repeated pain crises in 47 (36%), repeated acute chest syndrome in 5 (4%) and bone death in 3 (2%). Median age was 9.1 years. Ten-year overall survival was 94%. Event-free survival was 91%. With one conditioning regimen, overall survival was 97.4%. Acute graft-versus-host disease occurred in 20% and chronic disease in 9%. Among patients older than 13 at last follow-up, 46% had a long-term complication, including gonadal failure. Hydroxyurea use before transplant was described as variable in 60%. In the cerebral-vessel group, 52% were on monthly transfusion with iron removal (Al-Jefri et al., 2025).
A 2020 review said the same hospital had performed about 200 matched-sibling transplants for sickle cell disease by December 2018. The authors called that figure a centre questionnaire, not a registry extract (Alsultan et al., 2020). Across four leading Saudi transplant centres, 6,184 transplants of all kinds had been performed by late 2016, 5,340 of them at the Riyadh hospital, which opened its unit in 1984 (Aljurf et al., 2020).
These papers are mostly about children with a matched sibling. They do not say how many people aged 12 to 35 without a matched sibling are referred or declined. See also how chart reviews differ from a centre case series.
What is published about Casgevy?
On 9 January 2024 Vertex said the SFDA had authorised Casgevy for people aged 12 and older with sickle cell disease or transfusion-dependent beta-thalassemia. Vertex called it the first medicine through the SFDA breakthrough route and Vertex’s first Saudi approval. The note said Saudi Arabia has among the highest rates, “with thousands of patients.” One authorised treatment centre was already active. Vertex said it was working to qualify more hospitals, including King Faisal Specialist Hospital, and to secure formulary listing (Vertex). The same release, as carried by Nasdaq, names the Ministry of National Guard Health Affairs as that first centre (Nasdaq / Vertex).
The SFDA page still lists both indications, from age 12, and was last updated on 30 September 2026 (SFDA). The May 2024 handling guide, approved by the SFDA, restates the same age and indications (SFDA handling guide).
The public record does not give a treated-patient count. The SFDA lists a Phase 4 registry of patients treated with exa-cel (protocol 290-103, Vertex, status Ongoing as of 8 May 2025). The page does not publish how many people are in it (SFDA registry). A 2025 Delphi of 19 Saudi policymakers, clinicians, economists and formulary leads reached consensus on 88 statements about drugs for rare diseases. Budget limits ranked highest. The group also flagged uneven reimbursement and difficulty with managed-entry agreements (Abu Esba et al., 2025). That paper is not a Casgevy contract.

Payers already fund sickle cell care. One study of 217 Saudi adults in Dammam and Qatif estimated SAR 181,899 (US$48,506) per patient per year from a societal view: SAR 80,306 (US$21,415) for healthcare and SAR 101,594 (US$27,092) for lost work (Shdaifat et al., 2024). A chart review of 100 children (mean age 10.21; 96% HbSS) put mean annual direct medical cost at US$26,626, or US$14,605 after adjustment. In 12 months, 61% had at least one red-cell exchange, 45% at least one pain crisis, and 59% at least one hospital stay (Healthcare, 2025). A model that prices only the gene-therapy invoice leaves those costs out. See budget-impact work in Saudi Arabia.

What should a study ask?
| Workstream | Decision it answers | What the published record already shows | What to commission |
|---|---|---|---|
| Epidemiology and region | Which prevalence goes into the model | Premarital HbS was 4.7% in 2011–2018; Eastern SCD positivity was 9.8 per 1,000 in 2011–2015 (Aljabry et al., 2024; Alsaeed et al., 2018) | State the baseline and test Eastern, Jazan and other regions separately |
| Eligibility | How many patients fit the Casgevy label | SFDA indication is age 12+ with recurrent VOCs or TDT (SFDA) | Chart review of VOC count, genotype, transfusion and fitness |
| Hydroxyurea | What share is already modified | 56% prescribed in 2,816 Eastern records; 38.1% current use in a 202 Eastern survey (Alsaffar et al., 2024; Cureus 2022) | Dose, persistence and reason for stopping, by specialty |
| HSCT | What curative option already exists | 129 pediatric MRD transplants at KFSH&RC, 2006–2020, 10-year OS 94% (Al-Jefri et al., 2025) | Referral rules, donor availability and adult capacity |
| Payer and ATC | Who pays, and where it is infused | MNGHA was the first ATC; Vertex was still seeking formulary listing in January 2024 (Vertex / Nasdaq) | MOH, military/NG, CHI and hospital P&T as separate interviews |

State which baseline the model uses, and test the others. Split new cases from people already in care. Ask about age 12 and older, repeated pain crises or transfusion-dependent thalassemia, hydroxyurea use, and whether a matched sibling is available. Interview Ministry of Health, National Guard, military and private channels separately (PPRI).
Do not import a Gulf average. Compare the UAE, Egypt and Kuwait. A Saudi insurance answer is not an answer from another Gulf payer. Survey design is covered on physician surveys in Saudi Arabia.
How to brief BioNixus
BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. It has served 118 clients in 48 countries. It has run 127 studies so far in 2026. It works with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East. Custom studies are usually priced at $10k–$60k. Leadership offices are in Sheridan, Wyoming, London EC1V 2NX, and Sheikh Zayed, Giza. There are a field office for UAE in Dubai, a partner office for KSA in Al Khobar, and a field office for Kuwait in Salmiya. São Paulo is a field office for LATAM. Work in Latin America is covered today from the US office with local consultants.
The line “Guaranteed in writing” covers the agreed scope, timing and deliverables. It does not cover what the interviews will find. BioNixus has 40 client reviews.
See also pharmaceutical companies in Saudi Arabia, healthcare research firms in Saudi Arabia and the 2026 company list.
To brief a study, use the contact form or email admin@bionixus.com.
References
- Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia. Ann Saudi Med. 2011;31(3):229–235. doi:10.4103/0256-4947.81527. 1,572,140 people screened, 2004–2009. Source (accessed 13 October 2026).
- Memish ZA, Owaidah TM, Saeedi MY. Marked regional variations in the prevalence of sickle cell disease and β-thalassemia in Saudi Arabia: findings from the premarital screening and genetic counseling program. J Epidemiol Glob Health. 2011;1(1):61–68. Source (accessed 13 October 2026).
- Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9(6):372–377. doi:10.1097/GIM.0b013e318065a9e8. 488,315 people screened. Source (accessed 13 October 2026).
- Aljabry M, Sulimani S, Alotaibi G, Aljabri H, Alomary S, Aljabri O, Sallam M, Alsultan A. Prevalence and regional distribution of beta-hemoglobin variants in Saudi Arabia: insights from the national premarital screening program. J Epidemiol Glob Health. 2024;14(3):1242–1248. doi:10.1007/s44197-024-00281-x. 1,871,184 people, 2011–2018. Source (accessed 13 October 2026).
- Alsaeed ES, Farhat GN, Assiri AM, et al. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. J Epidemiol Glob Health. 2018;7(Suppl 1):S41–S47. Source (accessed 13 October 2026).
- Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011;31(3):289–293. doi:10.4103/0256-4947.81540. Reviews premarital versus Eastern newborn screening and the mild Eastern versus severe Western phenotypes. Source (accessed 13 October 2026).
- Al-Qurashi MM, El-Mouzan MI, Al-Herbish AS, Al-Salloum AA, Al-Omar AA. The prevalence of sickle cell disease in Saudi children and adolescents. A community-based survey. Saudi Med J. 2008;29(10):1480–1483. Source (accessed 13 October 2026).
- General Authority for Statistics (GASTAT). Population Estimates Statistics 2024 (English). Mid-2024: 35.3 million residents; 19.6 million Saudis; about 15.7 million non-Saudis. Source (accessed 13 October 2026).
- Al-Judaibi B, Alzahrani H, Alahmari A, et al. Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia. Saudi J Gastroenterol. 2025;31(2). Applies a 1–3 per 1,000 prevalence range to about 18.8 million Saudi nationals in the 2022 census to estimate 18,800–56,000 patients. Source (accessed 13 October 2026).
- Ministry of Health, Saudi Arabia. The Healthy Marriage Program (policy 005). Premarital screening and counselling mandated by Council of Ministers Resolution no. 4/B/54504 dated 15/11/1424 H. Source (accessed 13 October 2026).
- Al-Shroby WA, et al. Outcomes of the premarital screening program in Riyadh Region, KSA in 2021–2022: a cross-sectional study. J Family Med Prim Care. 2024. Notes more than 160 accredited governmental centres and more than 70 private centres nationwide. Source (accessed 13 October 2026).
- Alsaffar N, Alsaleh MA, Alsaleh AA, et al. Prescribing hydroxyurea in sickle cell disease patients: the pattern and association with co-prescribed medications used to manage the disease complications. J Clin Med. 2024;13(20):6254. doi:10.3390/jcm13206254. 2,816 patients at Al-Qatif Central Hospital and King Fahad Hospital, Hofuf, June 2021–May 2023; 56% hydroxyurea prescription. Source (accessed 13 October 2026).
- Impact of hydroxyurea therapy in reducing pain crises, hospital admissions, and length of stay among sickle cell patients in the Eastern Region of Saudi Arabia. Cureus. 2022;14(11):e31527. doi:10.7759/cureus.31527. 202 respondents; 38.1% currently using hydroxyurea. Source (accessed 13 October 2026).
- Gohal GA, Gosadi IM, Cittana Iqbal BA, et al. Utilization of hydroxyurea among patients diagnosed with sickle cell disease in Jazan, Saudi Arabia. Patient Prefer Adherence. 2022;16:3229–3239. More than 80% of participating parents said one or more of their children were receiving hydroxyurea. Source (accessed 13 October 2026).
- Al-Anazi A, et al. The impact of hydroxyurea on the rates of vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study. 156 patients; mean hydroxyurea dose 16.52 mg/kg/day; mean VOC reduction 1.36 events per patient per year. Source (accessed 13 October 2026).
- Bin-Saad K, et al. The role of hydroxyurea in decreasing the occurrence of vaso-occlusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia. Saudi Med J. 2020;41(1):46–52. 82 eligible children; 80% reduction in VOC and 73% shorter length of stay after hydroxyurea. Source (accessed 13 October 2026).
- Al-Jefri A, Al-Hashem F, Siddiqui K, et al. Hematopoietic stem cell transplantation in severe pediatric sickle cell disease: outcome and long-term complications, Saudi experience at King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Mediterr J Hematol Infect Dis. 2025. 129 matched-related-donor transplants, 2006–2020; 10-year OS 94%, EFS 91%. Source (accessed 13 October 2026).
- Alsultan A, et al. Hematopoietic stem cell transplantation for patients with sickle cell disease in the Eastern Mediterranean. Hematol Oncol Stem Cell Ther. 2020;13(2). Reports that KFSH&RC had performed approximately 200 matched-sibling SCD transplants by December 2018 (centre questionnaire). Source (accessed 13 October 2026).
- Aljurf M, et al. Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: experience from four leading tertiary care hematopoietic stem cell transplantation centers. Hematol Oncol Stem Cell Ther. 2021. KFSH&RC Riyadh 5,340 HSCTs to 2016; four centres 6,184. Source (accessed 13 October 2026).
- Vertex Pharmaceuticals. Vertex announces approval of first CRISPR/Cas9 gene-edited therapy, CASGEVY, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Kingdom of Saudi Arabia. 9 January 2024. SFDA marketing authorisation for people 12 years and older; first SFDA Breakthrough Designation; one authorized treatment centre already activated; working to qualify KFSH and to secure hospital-formulary listing. Source (accessed 13 October 2026).
- Vertex / Nasdaq press release, 9 January 2024. Names the Ministry of National Guard Health Affairs (MNGHA) as the first Authorized Treatment Center in Saudi Arabia and King Faisal Specialist Hospital as a centre Vertex was working to qualify. Source (accessed 13 October 2026).
- Saudi Food and Drug Authority. Drug approvals page for Casgevy. Indications: SCD in patients 12 years and older with recurrent vaso-occlusive crises; transfusion-dependent β-thalassemia in patients 12 years and older. Page last updated 30 September 2026. Source (accessed 13 October 2026).
- Saudi Food and Drug Authority. Registry-based study of patients treated with exagamglogene autotemcel (exa-cel) in the Kingdom of Saudi Arabia. Protocol 290-103; sponsor Vertex; Phase 4; status Ongoing as of 8 May 2025. Source (accessed 13 October 2026).
- Vertex / SFDA. CASGEVY handling and administration guide, Kingdom of Saudi Arabia, version 1.0. Date of preparation May 2024; approved by SFDA May 2024. Restates the 12+ SCD (recurrent VOC) and TDT indications. Source (accessed 13 October 2026).
- Abu Esba LC, Yousef CC, Khan MA, et al. Challenges in evaluation and reimbursement of drugs for rare diseases in Saudi Arabia: a Delphi expert consensus. J Pharm Policy Pract. 2025. Nineteen experts, January–February 2025; consensus on 88 statements across eight themes; economic and budgetary constraints the highest concern. Source (accessed 13 October 2026).
- Shdaifat E, Abu-Sneineh F, Alsaleh N, Ibrahim A. Economic burden of sickle cell disease in Saudi Arabia. Value Health Reg Issues. 2024;44:101038. doi:10.1016/j.vhri.2024.101038. 217 adults in the Eastern region; mean societal cost SAR 181,899 (US$48,506). Source (accessed 13 October 2026).
- The direct medical costs of sickle cell disease in Saudi Arabia: insights from a single center study. Healthcare (Basel). 2025;13(4):420. 100 patients, mean age 10.21 years, 96% HbSS; mean annual direct medical cost US$26,626; adjusted mean US$14,605. Source (accessed 13 October 2026).
- PPRI / Austrian National Public Health Institute. Healthcare system and pharmaceutical pricing in Saudi Arabia (2024). Describes SFDA pricing, NUPCO group purchasing, hospital Pharmacy and Therapeutics committees, and Council of Health Insurance control of private reimbursement. Source (accessed 13 October 2026).
- Council of Health Insurance. CHI Drug Formulary (Dhaman). Open formulary of SFDA-registered medicines; addition requests go through a hospital Pharmacy and Therapeutics Committee or the assigned medical director. Source (accessed 13 October 2026).
- U.S. Food and Drug Administration. FDA alerting patients and health care professionals about the voluntary withdrawal of Oxbryta (voxelotor) from the market. September 2024. Source (accessed 13 October 2026).
- European Medicines Agency. EMA recommends revoking authorisation of sickle cell disease medicine Adakveo (crizanlizumab). 26 May 2023. Source (accessed 13 October 2026).
- Grand View Research. Saudi Arabia hematology diagnostics market outlook. Public 2024 revenue USD 18.3 million (instrument and consumable sizing, not primary SCD or gene-therapy research). (accessed 13 October 2026).
- 6Wresearch. Saudi Arabia hematology diagnostics and hematology analyzer and reagents report pages. (accessed 13 October 2026).
- Ken Research. Saudi Arabia hematology diagnostics market report pages. (accessed 13 October 2026).





